OncoNano Medicine, Inc.

11:15 AM - 11:30 AM (PDT), Tuesday, June 14, 2022
OncoNano Medicine is developing a new class of pH-activated compounds that exploit the universal trait of acidity of the tumors. We are working collaboratively with pharmaceutical companies to develop new proprietary compounds employing our ON-BOARD technology to provide tumor specific delivery of cancer therapeutics including engineered antibodies and cytokines. The ability of our proprietary technology to specifically deliver payloads to tumor cells (and not to normal cells) has been demonstrated in our ongoing Ph2 trial imaging studies. In addition, OncoNano's other platform technology, OMNI, binds to the STING pathway to trigger an immune response, beneficial to a variety of payloads.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
Pegsitacianine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3